315 completed, 121 recruiting, 114 unknown, 106 active not recruiting. 813 Phase 3, 80 Phase 2.
By phase and status
Phase Trials Status Phase 3 813 Completed 315 , Recruiting 121 , Unknown 114 , Active not recruiting 106 , Terminated 105 , Not yet recruiting 31 , Withdrawn 16 , Enrolling by invitation 3 , Suspended 2 Phase 2 80 Completed 22 , Recruiting 19 , Unknown 16 , Active not recruiting 10 , Terminated 10 , Not yet recruiting 3
Follow Carcinoma, Non-Small-Cell Lung: new trials by email Literature Review of Carcinoma, Non-Small-Cell Lung trials Research Report on Carcinoma, Non-Small-Cell Lung
Trials (filtered) newest first · largest first
All 813 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma Phase 3 Recruiting 336 2027-03-02 2026-10-28 A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer Phase 3 Not yet recruiting 660 2027-01-06 2026-10-05 Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) Plinabulin, Docetaxel, Placebo (matching plinabulin placebo) - Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance Phase 3 Not yet recruiting 442 2026-12-01 2026-09-29 A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer Phase 3 Not yet recruiting 436 2026-12-01 2026-10-26 PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50% Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer Phase 3 Not yet recruiting 406 2026-11-30 2026-10-16 A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) Phase 2 / Phase 3 Not yet recruiting 1438 2026-11-30 2026-10-08 Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia Phase 2 / Phase 3 Not yet recruiting 950 2026-11-01 2026-10-28 A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung Phase 3 Not yet recruiting 448 2026-10-31 2026-09-16 A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC Adebrelimab (SHR-1316) + chemotherapy, Adebrelimab - Non-small Cell Lung Cancer (NSCLC) Phase 3 Not yet recruiting 1088 2026-10-31 2026-10-26 A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer JYP0322 Tablets, Crizotinib Capsules - NSCLC (Advanced Non-small Cell Lung Cancer) Phase 3 Not yet recruiting 216 2026-10-30 2026-09-22 Primary Radiotherapy In MEtastatic Lung Cancer Radiotherapy followed by chemotherapy, Standard of Care (SOC) - Carcinoma, Non-Small-Cell Lung (NSCLC) Phase 3 Recruiting 420 2026-10-30 2026-10-23 A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer Phase 3 Recruiting 400 2026-10-06 2026-10-13 Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy AMT-116, Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) - NSCLC (Advanced Non-small Cell Lung Cancer) Phase 2 / Phase 3 Recruiting 512 2026-09-30 2026-10-26 Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose - Metastatic NSCLC - Non-Small Cell Lung Cancer Phase 2 / Phase 3 Recruiting 230 2026-09-29 2026-10-28 A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer Phase 3 Recruiting 940 2026-09-22 2026-10-20 Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC Phase 3 Not yet recruiting 206 2026-09-17 2026-08-10 Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer Primary Tumor Resection, Osimertinib - Lung Neoplasms, Non-Small Cell Lung Cancer Phase 3 Recruiting 154 2026-09-08 2026-09-09 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer Phase 3 Recruiting 850 2026-09-08 2026-10-26 A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation lenvatinib pembrolizumab - NSCLC (Non-small Cell Lung Cancer)R Phase 3 Recruiting 15 2026-09-01 2026-09-09 A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) BL-B01D1, Osimertinib - Non-small Cell Lung Cancer Stage III Phase 3 Recruiting 418 2026-08-28 2026-09-10
Showing 20 of 813. Sign in to see all of them.
Narrower conditions Lung Neoplasms (188) · Neoplasms (35) · Adenocarcinoma of Lung (32) · Neoplasm Metastasis (30) · Parkinson Disease 4, Autosomal Dominant Lewy Body (21) · Brain Neoplasms (20) · Carcinoma (17) · Adenocarcinoma, Bronchiolo-Alveolar (14) · Lung Diseases (13) · Small Cell Lung Carcinoma (12) · Thoracic Neoplasms (11) · Breast Neoplasms (10) · Cachexia (10) · Carcinoma, Squamous Cell (10)
Broader conditions Respiratory Tract Diseases (806) · Carcinoma, Bronchogenic (805) · Neoplasms by Site (805) · Bronchial Neoplasms (804) · Respiratory Tract Neoplasms (804) · Thoracic Neoplasms (802) · Lung Diseases (800) · Neoplasms (778) · Lung Neoplasms (625) · Neoplasms, Glandular and Epithelial (68) · Neoplasms by Histologic Type (66) · Pathological Conditions, Signs and Symptoms (56) · Carcinoma (50) · Adenocarcinoma (38) · Pathologic Processes (36)
Interventions Carboplatin (216) · Cisplatin (177) · Pemetrexed (175) · Paclitaxel (139) · Docetaxel (124) · pembrolizumab (102) · Gemcitabine (80) · Erlotinib Hydrochloride (48) · Radiotherapy (42) · Gefitinib (37) · Vinorelbine (36) · Bevacizumab (32) · durvalumab (32) · Nivolumab (28) · osimertinib (26)
Sponsors Merck Sharp & Dohme LLC (39) · AstraZeneca (37) · Hoffmann-La Roche (35) · Eli Lilly and Company (25) · National Cancer Institute (NCI) (22) · Bristol-Myers Squibb (20) · Pfizer (17) · Alliance for Clinical Trials in Oncology (16) · Boehringer Ingelheim (14) · Novartis Pharmaceuticals (14) · Sun Yat-sen University (10) · AbbVie (8) · Intergroupe Francophone de Cancerologie Thoracique (8) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (8) · Radiation Therapy Oncology Group (8)
Countries United States (355) · China (342) · Italy (237) · Spain (236) · France (225) · Canada (218) · Germany (217) · South Korea (210) · Poland (198) · United Kingdom (194) · Taiwan (178) · Australia (169) · Brazil (166) · Japan (163) · Belgium (156)
Results publications PMID 37419867 , PMID 25881079 , PMID 37465924 , PMID 38642841 , PMID 40311309 , PMID 28472437 , PMID 28501139 , PMID 33337539 , PMID 34870327 , PMID 38468440 , PMID 41332393 , PMID 22266043 , PMID 22547591 , PMID 23948351 , PMID 25589191 , PMID 26051236 , PMID 26768165 , PMID 26823294 , PMID 26906526 , PMID 27130468 , PMID 27138015 , PMID 27601237 , PMID 29653820 , PMID 31395089 , PMID 32305010 , PMID 33075149 , PMID 33231285 , PMID 33300372 , PMID 34409776 , PMID 35073727 , PMID 35511917 , PMID 35930972 , PMID 36793385 , PMID 36795388 , PMID 37704166 , PMID 37922432 , PMID 38159809 , PMID 38383458 , PMID 39369790 , PMID 39661917 , PMID 39992021 , PMID 40421698 , PMID 40498298 , PMID 41666849 , PMID 41911908 , PMID 42335416 , PMID 42579028 , PMID 11786587 , PMID 11917283 , PMID 12377323
NIH funding 2023 (44) , 2014 (15) , 2018 (15) , 2017 (13) , 2015 (12) , 2019 (12) , 2025 (12) , 2009 (6) , U10CA031946 (6) , U10CA180821 (6) , U10CA180888 (6) , 2016 (5) , U10CA180820 (5) , 2005 (4) , U10CA021115 (4)